Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the COVID-19 Area: A Consensus of Iranian Experts
| Author | Farzad Pakdel | en |
| Author | Masoud Mardani | en |
| Author | Mohammadreza Salehi | en |
| Author | Sadegh Khodavaisy | en |
| Author | Azin Tabari | en |
| Author | Collaborating Authors Working Group | en |
| Orcid | Mohammadreza Salehi [0000-0002-1987-5929] | en |
| Orcid | Sadegh Khodavaisy [0000-0001-8039-4991] | en |
| Issued Date | 2022-08-31 | en |
| Abstract | Context: The current pandemic of COVID-19 affected all people of the world. Evidence Acquisition: Most complications of SARS-CoV-2 are causally related to severe pneumonia due to host immune response in the form of a cytokine storm. The other causes of an increased mortality rate among COVID-19 patients are secondary infections. Results: Mucormycosis is a life-threatening infection that gained much attention in the ongoing COVID-19 pandemic. A rise in the frequency of COVID-19-associated mucormycosis (CAM) occurred in 2020 and 2021. Overall, mortality of CAM has been reported as 54% - 75%. Conclusions: Although awareness of the disease has increased among treating physicians, disease-associated morbidity and mortality are still high. The guideline is intended to serve as a reference to prevent mucormycosis in COVID-19 patients and help healthcare providers choose diagnostic and treatment methods for the management of CAM cases. | en |
| DOI | https://doi.org/10.5812/archcid-127072 | en |
| URI | https://brieflands.com/journals/archcid/articles/127072 | en |
| Keyword | Mucormycosis | en |
| Keyword | COVID-19 | en |
| Keyword | Fungal Infection | en |
| Keyword | Coinfection | en |
| Keyword | Iran | en |
| Publisher | Brieflands | en |
| Title | Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the COVID-19 Area: A Consensus of Iranian Experts | en |
| Type | Review Article | en |